Cogstate is honored to be part of the program at the 2023 CTAD meeting in Boston.

We look forward to an exciting event with the opportunity to gather with colleagues and discuss new results and developments in the next generation of Alzheimer’s disease treatments.

Book a Meeting

Representatives from our clinical trials teams will be in attendance and would like to meet with you during the event. Cogstate has arranged an exclusive business suite next door to the conference hotel. Please reach out to your Cogstate contacts or submit this form and our team will reach out to make arrangements.

Cogstate Scientific Presentations at CTAD

For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world, with particular emphasis and experience in Alzheimer’s Disease. We are pleased to be part of the CTAD program.

  • Poster: A biomarker to aid Alzheimer’s disease staging: sTREM2 is decreased in Amyloid positive/Tau negative, yet increased once Tau aggregates leading to increased cognitive decline (Paul Maruff, Co-Author)
  • Poster: The Pre-Clinical Alzheimer’s Cognitive Composite Score: Informing Clinical Meaningfulness through the Alzheimer’s Disease Continuum (Paul Maruff, Co-Author)
  • Poster: Characterising progressive decline across multiple cognitive domains in preclinical Alzheimer’s disease (Paul Maruff, Co-Author)
  • Poster: Do Alzheimer’s Risk Genes Also Predict Cognitive Decline? (Paul Maruff, Co-Author)


Cogstate Experts Involved in Presentations

Paul Maruff, PhD

Paul Maruff, PhD

Chief Innovation Officer

View the full CTAD program here

How can we help you optimize the measurement of brain health?

Contact Our Team